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Analysis of Current Clinical Antiviral Treatment Approaches and Medications and Related Suggestions for Future Research
Daniel Sunderland, Department of Biology, Colby College, Waterville, Maine

Introduction

Immunomodulation

Resistance

• The term “virus” describes a group of nonliving
obligatorily-pathogenic particles that are capable of
infecting host cells, taking over their metabolic
machinery, and reproducing at the cost of the host’s own
energetic and molecular resources.
• The viral replication cycle has six basic steps:

• Immunomodulatory treatments are promising
because they may enhance innate immunity.
• Only interferon is prescribed for viral infection

• Interferon modulation

•
•
•
•
•

adsorption,
penetration/uncoating,
viral component replication
assembly, and
release

• Treatment methods fall into discrete categories, all based
on known viral infection and replication methods, to
slow the replication and spread of the virus.
http://www.scientificamerican.com/article/treating-hiv/

The rapid and incredibly prolific nature of viral replication allows for greater variation, and thus greater
rates of resistance development. HAART and other “cocktail” treatments aim to stall viral replication at
different levels, decreasing the chance that resistant strains will persist. A virus would have to have three
separate resistance mechanisms simultaneously to continue unhindered in these cases.

Direct Treatment Methods
• Spike protein antagonists
•

Creating antibodies that will bind to the spike proteins or
cellular receptors – expensive and incredibly timeconsuming

•

• GCSF is generally used to help cancer patients
23
recover from chemotherapy , though it could also
be used to increase immunological response,
especially in advanced AIDS patients.
•

•

•

Toxic nucleosides such as acyclovir (guanosine
analogue) is used to treat the herpes simplex virus,
varicella zoster, herpes zoster, and sometimes HIV19.
Acyclovir halts DNA production because it lacks a 3’
end12. Azidothymidine (AZT) is a thymine analog
recognized by reverse-transcriptase and used in HIV
treatment22.
Integrase inhibitors, including raltegravir, dolutegravir,
and elvitegravir, prevent viral genes from being spliced
into the host genome by selectively inhibiting the strand
transfer ability of integrase17, but side effects and/or liver
dysfunction and failure have been reported3.
Protease inhibitors prevent the post-translational
conversion of viral gene products to their mature form4.

• Highly active antiretroviral therapy (HAART), used to
treat HIV, is comprised of two different NRTIs and one
protease or integrase34.
•

The combination decreases viral load, decreasing the
likelihood of resistance and allowing the patient’s
immune system to rebuild.

• Neuraminidase inhibitors such as oseltamivir target the
detachment mechanism of influenza viruses.
Neuraminidase must cleave the hemagglutinin-sialic acid
bond to release new virions27.

GCSF has been shown to cause Sweet’s Syndrome,
an autoimmune condition25. Further study would be
needed to confirm efficacy in a virology setting.

•

It activates (TLR7), acting upstream of interferon in
the immune signaling pathway and triggering the
release of several cytokines6. Its efficacy against
viral infections is largely unknown.

•
•

These compounds have been shown to increase the
immune response. Sulfated polysaccharides from
Enteromorpha prolifera and the red seaweed
Nemalion helminthoides were shown to increase the
proliferation of macrophages and stimulated nitric
oxide and cytokine production14,24.

Inhibits the viral M2 ion channel needed to uncoat
influenza A viruses after host cell penetration32
Amantadine is no longer recommended because due to
widespread resistance, particularly in all relevant strains
of H1N19. Amantadine was highly encouraged as both a
prophylactic and a treatment as early as the 1970s20.

• Raltegravir was hailed as major progress in the search
16
for new integrase inhibitors in 2005 and has now been
3
approved for use in very young children .
•

Merck & Co. are currently researching MK-2048, a
compound they refer to as a “second generation integrase
inhibitor,” capable of lasting up to four hours longer than
raltegravir18.

• Oseltamivir can be seen in the very early stages of this
resistance process.
•

• Sulfated polysaccharides as immunomodulatory
elements
•

Example: A Borna virus nucleoprotein inhibits interferon
production by counteracting the TBK1–IRF3 pathway31.

• Amantadine and rimantadine

• Imiquimod is prescribed as a topical cream to treat
warts and other skin irritations7.

• Disruption of Replication
•

Natural interferons are released by a cell infected by
a viral pathogen to warn nearby cells, triggering a
series of non-specific antiviral genes8.

•

A factsheet produced by Roche in 2006 claimed that
resistance was infrequent at that time28. As of 2009, the
WHO believes that “there is no evidence to indicate the
development of widespread antiviral resistance among
pandemic H1N1 viruses”33.

• Some viruses have also developed resistance to acyclovir
5
and penciclovir , which act at a very direct level on viral
replication mechanisms, after decades of treatment.

http://en.wildeyes.be/photo.php?id=423

Generalized
Influenza
Virus

Neuraminidase
http://www.cmaj.ca/content/183/7/E420.figures-only

Oseltamivir and zanamivir are competitive neuraminidase inhibitors. Some H1N1
oseltamivir resistance has been reported, but none for zanamivir thus far.
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Enteromorpha prolifera and Nemalion helminthoides
contain sulfated polysaccharides that may increase the
immune response to viruses and other pathogens.
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Hemagglutinin

Viral Vectors
• The persistence of viral infections, such as dengue
fever in the more arid parts of the world, can be
directly attributed to non-human vectors in those
areas.
• A recent study explored the immune response of the
Aedes aegypti mosquito when it has been infected by
dengue virus13.
•

Two genes silenced in A. aegypti elevated resistance
to the virus in the mosquito’s midgut, suggesting
that the virus affected the immune response of the
host by somehow modulating the expression of
those genes.

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.

AIDSinfo. (2013, August 23). Dolutegravir. Retrieved from AIDSinfo Drug Database: http://aidsinfo.nih.gov/drugs/509/dolutegravir/0/patient
AIDSinfo. (2013, May 29). Elvitegravir. Retrieved from AIDSinfo Drug Database: http://aidsinfo.nih.gov/drugs/421/elvitegravir/0/patient
AIDSinfo. (2014, February 4). Raltegravir. Retrieved from AIDSinfo Drug Database: http://aidsinfo.nih.gov/drugs/420/raltegravir/0/patient
Anderson, J. e. (2009). Viral Protease Inhibitors. In H.-G. &. Krausslich (Ed.), Antiviral Strategies (Vol. 189, pp. 85-110). Heidelberg, Germany: Springer.
Bacon, T. H. (2003, January). Herpes Simplex Virus Resistance to Acyclovir and Penciclovir after Two Decades of Antiviral Therapy. Clinical Microbiology Reviews, 114-128.
Bilu, D., & Sauder, D. N. (2003). Imiquimod: modes of action. Br J Dermatol., Supplement 5-8.
Daily Med Website. (2007, April). aldara (imiquimod) cream for topical use. (National Institutes of Health) Retrieved from Daily Med Website: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7fccca4efb8f-42b8-9555-8f78a5804ed3
Feld, J. J., & Hoofnagle, J. H. (2005, August 18). Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature, 436, 967-972.
Fiore, A. E. (2011, January 21). Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza. Retrieved February 1, 2014, from Centers for Disease Control and Prevention:
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6001a1.htm
Fleming, A. (1945, December 11). Penicillin. Retrieved from Nobel Prize Website: http://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdf
Furman, P. A. (1986, November). Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proceedings of the
National Academy of Science, 83, 8333-8337.
Gnann, J. W. (1983). Acyclovir: Mechanism of Action, Pharmokinetics, Safety and Clinical Applications. Pharmacotherapy, 275-283.
Jupatanakul, N. e. (2013, October 3). Aedes aegypti ML and Niemann-Pick type C family members are agonists of dengue virus infection. Developmental and Comparitive Immunology, 1-9.
Kim, J.-K. e. (2011, September 2). In vitro and in vivo immunomodulatory activity of sulfated polysaccharides from Enteromorpha prolifera. International Journal of Biological Macromolecules, 1051-1058.
Kramer, M. e. (2003). Metabolic engineering for microbial production of shikimic acid. Metabolic Engineering, 277-283.
Levin, J. (2005). MK-0518, the first Integrase Inhibitor for HIV, No Blarney. Dublin: National AIDS Treatment Advocacy Project.
Malet, I. e. (2012). The future of integrase inhibitors of HIV-1. Current Opinion in Virology, 580-587.
Mascolini, M. (2009). Merck Offers Unique Perspective on Second-Generation Integrase Inhibitor. Amsterdam: National AIDS Treatment Advocacy Project.
Mascolinli, M., & Kort, R. (2010). 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: summary of key research and implications for policy and practice - Biomedical
prevention. Journal of the International AIDS Society, Supplement1.
Maugh, T. H. (1979, November). Panel Urges Wide Use of Antiviral Drug. Science, 26(4422), 1058-1060.
Medline Plus. (2010, September 1). Acyclovir. Retrieved from Medline Plus: http://www.nlm.nih.gov/medlineplus/druginfo/meds/a681045.html#side-effects
Mitsuya, H. e. (1990, September 28). Molecular Targets for AIDS Therapy. Science, 249(4976), 1533-1544. Retrieved February 3, 2014, from http://www.jstor.org/stable/2877810
Parry, T. (2009). Network GCSF Guidelines. North Wales Cancer Network.
Pérez-Recalde, M. e. (2013, October 26). In vitro and in vivo immunomodulatory activity of sulfated polysaccharides from red seaweed Nemalion helminthoides. International Journal of Biological
Macromolecules, 38-42.
Paydaş S. et al. (September 1993). "Sweet's syndrome associated with G-CSF". Br. J. Haematol. 85 (1): 191–2.
Song, W. e. (2013, August 11). Borna disease virus nucleoprotein inhibits type I interferon induction through the interferon regulatory factor 7 pathway. Biochemical and Biophysical Research Communications,
619-623.
Svitil, K. (2010, June 3). Caltech Biologists Provide Molecular Explanation for the Evolution of Tamiflu Resistance. Retrieved from CalTech Website: http://www.caltech.edu/content/caltech-biologists-providemolecular-explanation-evolution-tamiflu-resistance
The Roche Group. (2006, November 17). Factsheet Tamiflu. Retrieved November 14, 2013, from Roche Website: http://www.roche.com/med_mbTAMIFLU05e.pdf
United States Food and Drug Administration. (1999). NDA 21-087. Rockville, MD: United States Food and Drug Association.
United States Food and Drug Administration. (2012, December 21). FDA expands Tamiflu’s use to treat children younger than 1 year. Retrieved February 2, 2014, from Food and Drug Administration Website:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333205.htm
Unterstab, G. e. (2005, September 20). Viral targeting of the interferon-β-inducing Traf family member-associated NF-κB activator (TANK)-binding kinase-1. Proceedings of the National Academy of Sciences,
102(38), 13640-13645.
Wang, C. e. (1993, September). Ion Channel Activity of Influenza A Virus M2 Protein: Characterization of the Amantadine Block. Journal of Virology, 67(9), 5585-5594.
World Health Organization. (2009, July 8). Viruses resistant to oseltamivir (Tamiflu) identified. Retrieved November 14, 2013, from World Health Organization Website:
http://www.who.int/csr/disease/swineflu/notes/h1n1_antiviral_resistance_20090708/en/
World Health Organization. (2013, June). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. Retrieved from World
Health Organization Website: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1

Acknowledgements
I would like to thank Professor of Biology Frank Fekete for sponsoring this independent study and the librarians who helped me
acquire journal articles outside the normal scope of what is available at Colby College.

